PRN.TO - Profound Medical Corp.

Toronto - Toronto Delayed Price. Currency in CAD
0.7200
0.0000 (0.00%)
As of 1:17PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.7200
Open0.7200
Bid0.7100 x 0
Ask0.7300 x 0
Day's Range0.7200 - 0.7200
52 Week Range0.4600 - 1.0700
Volume1,200
Avg. Volume48,142
Market Cap77.8M
Beta (3Y Monthly)2.61
PE Ratio (TTM)N/A
EPS (TTM)-0.1740
Earnings DateMay 8, 2019 - May 13, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.03
  • If You Had Bought Profound Medical (TSE:PRN) Stock Three Years Ago, You'd Be Sitting On A 50% Loss, Today
    Simply Wall St.8 days ago

    If You Had Bought Profound Medical (TSE:PRN) Stock Three Years Ago, You'd Be Sitting On A 50% Loss, Today

    The truth is that if you invest for long enough, you're going to end up with some losing stocks. But long term...

  • GlobeNewswire9 days ago

    Profound Medical Sells First TULSA-PRO® System in Japan

    OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, today announced that it has sold its first TULSA-PRO® system in Japan. The system was purchased by Hokuyu Hospital in Sapporo via Japan's Pharmaceutical and Medical Device (“PMD”) Act’s expanded access program.

  • GlobeNewswirelast month

    Profound Medical Annual and Special Meeting of Shareholders Voting Results

    OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, is pleased to announce the results of the votes on the matters considered at its Annual and Special Meeting of Shareholders that was held today (the “Meeting”). A total of 65,503,023 common shares, representing 60.6% of the shares outstanding, were represented in person and by proxy at the Meeting. All of the matters put forward before the shareholders, as set out in the Company's management information circular dated May 6, 2019, were approved by the requisite majority of votes cast at the Meeting.

  • Are Profound Medical Corp.'s (TSE:PRN) Interest Costs Too High?
    Simply Wall St.last month

    Are Profound Medical Corp.'s (TSE:PRN) Interest Costs Too High?

    Investors are always looking for growth in small-cap stocks like Profound Medical Corp. (TSE:PRN), with a market cap...

  • GlobeNewswire2 months ago

    Profound Medical Announces First Quarter 2019 Financial Results

    - Receives Notification of FDA Acceptance of 510(k) Application Filing for TULSA-PRO® - TORONTO, May 06, 2019 -- Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or.

  • GlobeNewswire3 months ago

    Profound Medical to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference

    OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, announced today that management will present an update on the Company’s business at the 2019 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 30, 2019 at 3:30 p.m. Eastern Time at the Metro Toronto Convention Centre. The presentation will be broadcast live and archived on the Company's website at www.profoundmedical.com under "Webcasts" in the Investors section. Profound develops and markets customizable, incision-free therapies for the ablation of diseased tissue.

  • GlobeNewswire3 months ago

    Profound Medical to Release First Quarter 2019 Financial Results on May 6 – Conference Call to Follow

    OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, will announce its first quarter 2019 financial results after market close on Monday, May 6, 2019. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. Profound develops and markets customizable, incision-free therapies for the ablation of diseased tissue.

  • Profound Medical Corp. (TSE:PRN): Will The Growth Last?
    Simply Wall St.3 months ago

    Profound Medical Corp. (TSE:PRN): Will The Growth Last?

    The most recent earnings update Profound Medical Corp.'s (TSE:PRN) released in December 2018 confirmed that losses became smaller relative to the prior year's level as a result of recent tailwinds...

  • GlobeNewswire3 months ago

    Profound Medical Announces First-of-its-Kind TULSA-PRO® Installation

    OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, today announced that the first prostate cancer treatment using a first-of-its-kind TULSA-PRO® installation has been performed in Trier, Germany.

  • Foundation Chairman Shares Focused Ultrasound Growth at Inaugural Global Investor Conference
    PR Newswire3 months ago

    Foundation Chairman Shares Focused Ultrasound Growth at Inaugural Global Investor Conference

    CHARLOTTESVILLE, Va., April 15, 2019 /PRNewswire/ -- Focused Ultrasound Foundation Chairman Neal F. Kassell, MD, was the keynote speaker at Analyst & Investor Day at the University Club in New York, NY, on April 11. The event was a first-of-its-kind gathering in the field of focused ultrasound and included key researchers, clinicians, financial analysts and institutional investors from around the world. The meeting was hosted by Profound Medical Corp., which provides a therapeutic platform combining real-time magnetic resonance imaging and ultrasound technology for the precise, incision-free ablation of diseased tissue.

  • GlobeNewswire3 months ago

    Profound Medical Analyst & Investor Day Agenda

    TORONTO, April 08, 2019 -- Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which.

  • GlobeNewswire3 months ago

    Profound Medical Announces Positive Topline Results from TACT Pivotal Clinical Trial of TULSA-PRO® in Patients with Prostate Cancer

    OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, today announced positive topline results from the TACT (TULSA-PRO® Ablation Clinical Trial) pivotal study designed to support its application to the U.S. Food and Drug Administration (“FDA”) for 510(k) clearance to market TULSA-PRO® in the United States. TACT, a prospective, open-label, single-arm pivotal clinical study, enrolled 115 patients with biopsy-proven, organ-confined prostate cancer across 13 research sites in the U.S., Canada and Europe. Primary and key secondary endpoints are determined at 12 months post-treatment, but patient quality of life and disease control will be followed per-protocol to 5 years.

  • GlobeNewswire4 months ago

    Profound Medical Announces Fourth Quarter and Full Year 2018 Financial Results

    TORONTO, March 07, 2019 -- Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the.

  • Should You Worry About Profound Medical Corp.’s (TSE:PRN) CEO Pay?
    Simply Wall St.4 months ago

    Should You Worry About Profound Medical Corp.’s (TSE:PRN) CEO Pay?

    In 2016 Arun Menawat was appointed CEO of Profound Medical Corp. (TSE:PRN). This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. After that,Read More...

  • GlobeNewswire5 months ago

    Save the Date: Profound Medical to Host Inaugural Analyst & Investor Day on April 11

    OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that combines real-time Magnetic Resonance (“MR”) imaging and ultrasound technology for the precise, incision-free ablation of diseased tissue, will host its first Analyst & Investor Day on Thursday, April 11, 2019. “The program will feature presentations on TULSA-PRO® from key opinion leaders in the United States who have gained first-hand experience with the technology as investigators for the TACT trial and from current commercial users in Europe,” commented Arun Menwat, Profound’s CEO. For individuals who are unable to attend the meeting in person, a live webcast will be available on the Company’s website at www.profoundmedical.com under "Webcasts" in the Investor Relations section.

  • GlobeNewswire5 months ago

    Profound Medical to Release Fourth Quarter and Full Year 2018 Financial Results on March 7 – Conference Call to Follow

    OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that combines real-time Magnetic Resonance (“MR”) imaging and ultrasound technology for the precise, incision-free ablation of diseased tissue, will announce its fourth quarter and full year 2018 financial results after market close on Thursday, March 7, 2019. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. Profound is developing the powerful combination of real-time magnetic resonance (MR) imaging and non-invasive ultrasound ablation.

  • How Much Money Does Profound Medical Corp. (TSE:PRN) Make?
    Simply Wall St.6 months ago

    How Much Money Does Profound Medical Corp. (TSE:PRN) Make?

    If you are currently a shareholder in Profound Medical Corp. (TSE:PRN), or considering investing in the stock, you need to examine how the business generates cash, and how it is Read More...

  • GlobeNewswire6 months ago

    Profound Medical Announces Preliminary Unaudited Fourth Quarter 2018 Revenues

    OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that combines real-time Magnetic Resonance (“MR”) imaging and ultrasound technology for the precise, incision-free ablation of diseased tissue, today announced preliminary unaudited revenues for the fourth quarter of 2018. Profound is providing this information due to the significant lag time between planned investment community meetings to be held in connection with, among other non-deal investor events, the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA, and its expected reporting of final 2018 results in March 2019. “The initial commercial launch of Sonalleve® in China, combined with growing interest from European doctors, clinics and patients in TULSA-PRO®, led to this significant rebound in quarterly revenues,” said Arun Menawat, Profound’s CEO.

  • Read This Before Selling Profound Medical Corp. (TSE:PRN) Shares
    Simply Wall St.7 months ago

    Read This Before Selling Profound Medical Corp. (TSE:PRN) Shares

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On the other hand, we'd be remiss not to mention Read More...

  • GlobeNewswire7 months ago

    Profound Medical Announces Changes to Commercial Organization

    “We expect a seamless transition as Hartmut Warnken, our VP of International Sales, will assume overall commercial management responsibility for those jurisdictions where our technologies are currently cleared for marketing - Europe, where our focus remains on driving clinical adoption of TULSA-PRO® for treating prostate disease and Asia, where we recently initiated the launch of Sonalleve® for the treatment of uterine fibroids. Profound is developing and commercializing therapeutic platforms that combine the power of real-time magnetic resonance (MR) imaging and non-invasive ultrasound ablation.

  • GlobeNewswire8 months ago

    Profound Medical Announces Third Quarter 2018 Financial Results

    Prepares for First Sonalleve® Shipment to China TORONTO, Nov. 08, 2018 -- Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to.

  • Simply Wall St.8 months ago

    Do Institutions Own Shares In Profound Medical Corp (TSE:PRN)?

    Every investor in Profound Medical Corp (TSE:PRN) should be aware of the most powerful shareholder groups. Institutions often own shares in more established companies, while it’s not unusual to see Read More...

  • ACCESSWIRE8 months ago

    Profound Medical to Present at the 2018 Canaccord Genuity Medical Technologies & Diagnostics Forum

    OTCQX: PRFMF) ("Profound" or the "Company"), the only company to provide a therapeutics platform that provides the precision of real-time Magnetic Resonance ("MR") imaging combined with the safety and ablation power of directional and focused ultrasound technology for the incision-free ablation of diseased tissue, announced today that management will present an update on the Company's business at the 2018 Canaccord Genuity Medical Technologies & Diagnostics Forum on Thursday, November 15, 2018, at 1:00 p.m. Eastern Time at the Westin Grand Central Hotel, New York, NY. The presentation will be broadcast live and archived on the Company's website at www.profoundmedical.com under "Webcasts" in the Investor Relations section.

  • GlobeNewswire8 months ago

    Profound Medical to Present at the Stifel 2018 Healthcare Conference

    OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time Magnetic Resonance (“MR”) imaging combined with the safety and ablation power of directional and focused ultrasound technology for the incision-free ablation of diseased tissue, announced today that management will present an update on the Company’s business at the Stifel 2018 Healthcare Conference on Wednesday, November 14, 2018, at 8:45 a.m. Eastern Time at the Lotte New York Palace Hotel in New York City. The presentation will be broadcast live and archived on the Company's website at www.profoundmedical.com under "Webcasts" in the Investor Relations section.

  • GlobeNewswire9 months ago

    Profound Medical to Release Third Quarter 2018 Financial Results on November 8 – Conference Call to Follow

    OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time Magnetic Resonance (“MR”) imaging combined with the safety and ablation power of directional and focused ultrasound technology for the incision-free ablation of diseased tissue, will announce its third quarter 2018 financial results after market close on Thursday, November 8, 2018. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. The call will also be broadcast live and archived on the Company's website at www.profoundmedical.com under "Webcasts" in the Investor Relations section.